Zobrazeno 1 - 10
of 96
pro vyhledávání: '"John M Rossi"'
Autor:
Michael Wang, Preetesh Jain, T Linda Chi, Sheree E Chen, Amy Heimberger, Shiao-Pei Weathers, Lianqing Zheng, Arati V Rao, John M Rossi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We descr
Externí odkaz:
https://doaj.org/article/b9c79dd65c64418584175a12ac69626d
Autor:
Scott D Patterson, John M Rossi, Katherine L Paweletz, V Dan Fitzpatrick, C Glenn Begley, Leigh Busse, Steve Elliott, Ian McCaffery
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0122149 (2015)
Several clinical trials in oncology have reported increased mortality or disease progression associated with erythropoiesis-stimulating agents. One hypothesis proposes that erythropoiesis-stimulating agents directly stimulate tumor proliferation and/
Externí odkaz:
https://doaj.org/article/cfa6893608d54c5d9b9b086c3645e23b
Autor:
Armin Ghobadi, Jack H. Landmann, Alun Carter, Matthew L. Cooper, Mehmet Emrah Selli, Jufang Chang, Matthew Baker, Christopher A. Miller, Francesca Ferraro, David Y. Chen, Amanda M. Smith, Taylor A. LaValle, Eric J. Duncavage, Justin Chou, Victor Tam, Joseph M. Benoun, Jenny Nater, Nathalie Scholler, Francesca Milletti, Remus Vezan, Adrian Bot, John M. Rossi, Nathan Singh
Publikováno v:
Blood Advances. 6:5634-5640
Autor:
Nathalie Scholler, Regis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot, Jérôme Galon
Publikováno v:
Nature Medicine. 28:1872-1882
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient s
Autor:
Joshua D. Brody, Brian D. Brown, Miriam Merad, Alessia Baccarini, Alessandro Lagana, Samir Parekh, Norah Sadek, John M. Rossi, Adrian Bot, Nathalie Scholler, Sherry Bhalla, Aleksandra Wroblewska, Matthew J. Lin, Judit Svensson-Arvelund, Gvantsa Pantsulaia, Jonathan A. Boiarsky, Ranjan Upadhyay
Supplementary Figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5717e61e5a43e124c9769aa837dffa8b
https://doi.org/10.1158/2159-8290.22536655
https://doi.org/10.1158/2159-8290.22536655
Autor:
Joshua D. Brody, Brian D. Brown, Miriam Merad, Alessia Baccarini, Alessandro Lagana, Samir Parekh, Norah Sadek, John M. Rossi, Adrian Bot, Nathalie Scholler, Sherry Bhalla, Aleksandra Wroblewska, Matthew J. Lin, Judit Svensson-Arvelund, Gvantsa Pantsulaia, Jonathan A. Boiarsky, Ranjan Upadhyay
T cell–based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49aa3046b7b18a4b4f9c494b28da690
https://doi.org/10.1158/2159-8290.c.6548197.v1
https://doi.org/10.1158/2159-8290.c.6548197.v1
Autor:
Joshua D. Brody, Brian D. Brown, Miriam Merad, Alessia Baccarini, Alessandro Lagana, Samir Parekh, Norah Sadek, John M. Rossi, Adrian Bot, Nathalie Scholler, Sherry Bhalla, Aleksandra Wroblewska, Matthew J. Lin, Judit Svensson-Arvelund, Gvantsa Pantsulaia, Jonathan A. Boiarsky, Ranjan Upadhyay
Supplementary Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2977007af1d70e51df9d2c5b7ae2af9d
https://doi.org/10.1158/2159-8290.22536652.v1
https://doi.org/10.1158/2159-8290.22536652.v1
Autor:
Caron A, Jacobson, Julio C, Chavez, Alison R, Sehgal, Basem M, William, Javier, Munoz, Gilles, Salles, Pashna N, Munshi, Carla, Casulo, David G, Maloney, Sven, de Vos, Ran, Reshef, Lori A, Leslie, Ibrahim, Yakoub-Agha, Olalekan O, Oluwole, Henry Chi Hang, Fung, Joseph, Rosenblatt, John M, Rossi, Lovely, Goyal, Vicki, Plaks, Yin, Yang, Remus, Vezan, Mauro P, Avanzi, Sattva S, Neelapu
Publikováno v:
The Lancet Oncology. 23:91-103
Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma.ZU
Autor:
Irit Avivi, Tom van Meerten, Jenny J. Kim, Marika Sherman, John M. Rossi, Roch Houot, Monique C. Minnema, Jinghui Dong, Martin Wermke, John Kuruvilla, Yan Zheng, Max S. Topp, Kevin W. Song, Saran Vardhanabhuti, Ulrich Dührsen, Adrian Bot, Marie José Kersten, Vicki Plaks, Anne Kerber, Catherine Thieblemont, Pieternella J. Lugtenburg, Krimo Bouabdallah
Publikováno v:
British journal of haematology, 195(3), 388-398. Wiley-Blackwell
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel–related toxicity, several exploratory safety managem
Autor:
Deepa Jeyakumar, Ryan D. Cassaday, Roch Houot, Chaoling Feng, Dimitrios Tzachanis, Maria R. Baer, John M. Rossi, Patrick J. Stiff, Marion Subklewe, Max S. Topp, Behzad Kharabi Masouleh, Bijal D. Shah, Remus Vezan, Martha Arellano, Olalekan O. Oluwole, Aaron C Logan, William G. Wierda, Kristen M. O'Dwyer, Tong Shen, Monique C. Minnema, Jinghui Dong, Daniel J. DeAngelo, Nicolas Boissel, Mehrdad Abedi, Francesca Milletti, Gary J. Schiller, Thibaut Leguay, Armin Ghobadi, Michael R. Bishop, Yi Lin, Jae H. Park
Publikováno v:
Lancet
Lancet, Elsevier, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
The Lancet
The Lancet, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
Lancet, Elsevier, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
The Lancet
The Lancet, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
International audience; BACKGROUND: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, und